Clinical application of interventional renal sympathetic denervation: recommendations of the Austrian Society of Hypertension 2012
| Autor: | Katharina Hohenstein, Johann Auer, Helmut Brussee, Thomas Lambert, Peter Grüner, Bruno Watschinger, Jörg H. Horina, Thomas Weber, Mathias C. Brandt, Uta C. Hoppe, Robert Zweiker, Christian Koppelstätter |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Sympathetic nervous system Hypertension Renal Percutaneous business.industry General Medicine Kidney Pathophysiology Clinical trial Blood pressure medicine.anatomical_structure Renal sympathetic denervation Austria Internal medicine Adventitia Practice Guidelines as Topic Cardiology Humans Medicine Sympathectomy business Intensive care medicine Adverse effect |
| Zdroj: | Wiener klinische Wochenschrift. 124:789-798 |
| ISSN: | 1613-7671 0043-5325 |
| Popis: | Increased activity of the sympathetic nervous system plays a major role in the pathophysiology of primary arterial hypertension. Interventional renal sympathetic denervation (RSD) is a novel percutaneous treatment, decreasing sympathetic activity and consecutively blood pressure by ablating sympathetic nervous fibers located in the adventitia of the renal arteries. The procedure has been tested in several clinical trials in patients with resistant hypertension (defined as systolic office blood pressure > 160 mmHg—in diabetic patients > 150 mmHg—treated with ³ 3 antihypertensive drugs) and caused a meaningful blood pressure reduction, lasting for at least 3 years. So far, no major adverse events have been identified; however, data on the long-term consequences are lacking. The present position paper of the Austrian Society of Hypertension is aiming to assist in choosing possible indications for RSD in clinical routine, based on the available evidence in 2012. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink